Effect of the recombinant human endostatin injection combined with EP chemotherapy and intensity-modulated radiotherapy in patients with advanced non-small cell lung cancer

ObjectiveTo investigate the value of recombinant human endostatin injection combined with EP chemotherapy(etoposide and cisplatin) and intensity-modulated radiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).

MethodsNinety-eight patients with advanced NSCLC were divided into the observation group and control group according to the random number table method (49 cases in each group).The control group was treated with the EP chemotherapy combined with intensity-modulated radiotherapy, and the observation group was additionally treated with the recombinant human endostatin injection on the basis of control group.The response rate, disease control rate, serum levels of cytokeratin 19 fragment 21-1(CYFRA21-1), carbohydrate antigen 50(CA50) before and after treatment and quality of life were compared between two groups.All cases were followed up for 2 years, and the survival between two groups was compared.

ResultsThe effective rates of treatment in observation group and control group were 63.27% and 51.02%, respectively, and the difference of which was not statistically significant(P>0.05).The disease control rate in observation group(89.80%) was higher than that in control group(71.43%)(P < 0.05).After treatment, the serum levels of CYFRA21-1 and CA50 in observation group were lower than those in control group(P < 0.01), and the improvement rate of survival quality in observation group(61.22%) was higher than that in control group(40.82%)(P < 0.05).The median survival time in observation group and control group were 14 months and 11 months, respectively.The 1-year and 2-year survival rates in observation group and control group were 59.57%, 34.04% and 47.83%, 26.09%, respectively, and the difference of which between two groups was not statistically significance(P>0.05).

ConclusionsThe EP chemotherapy, intensity-modulated radiotherapy combined with recombinant human endostatin injection in the treatment of advanced NSCLC can effectively improve the disease control rate, down-regulate the serum levels of CYFRA21-1 and CA50, and improve the quality of life of patients, but it can not significantly improve the survival rate of patients.